This high mutation rate indicates tumour suppressive roles, which leads to the question of how perturbations of SWI/SNF chromatin remodellers contribute to tumourigenesis, how they promote tumour growth and, more importantly, whether SWI/SNF complexes can be targeted therapeutically. The gene discussed is SMARCA1; the disease is neoplasm.